These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. What have we learned from basic science studies on idiopathic pulmonary fibrosis? Yanagihara T; Sato S; Upagupta C; Kolb M Eur Respir Rev; 2019 Sep; 28(153):. PubMed ID: 31511255 [TBL] [Abstract][Full Text] [Related]
6. Transcriptomic profiling reveals disease-specific characteristics of epithelial cells in idiopathic pulmonary fibrosis. Boesch M; Baty F; Brutsche MH; Tamm M; Roux J; Knudsen L; Gazdhar A; Geiser T; Khan P; Hostettler KE Respir Res; 2020 Jun; 21(1):165. PubMed ID: 32605572 [TBL] [Abstract][Full Text] [Related]
7. Recent advances in molecular targets and treatment of idiopathic pulmonary fibrosis: focus on TGFbeta signaling and the myofibroblast. Gharaee-Kermani M; Hu B; Phan SH; Gyetko MR Curr Med Chem; 2009; 16(11):1400-17. PubMed ID: 19355895 [TBL] [Abstract][Full Text] [Related]
9. Epithelium-dependent profibrotic milieu in the pathogenesis of idiopathic pulmonary fibrosis: current status and future directions. Xu X; Dai H; Wang C Clin Respir J; 2016 Mar; 10(2):133-41. PubMed ID: 25047066 [TBL] [Abstract][Full Text] [Related]
10. Idiopathic Pulmonary Fibrosis: Pathogenesis and the Emerging Role of Long Non-Coding RNAs. Hadjicharalambous MR; Lindsay MA Int J Mol Sci; 2020 Jan; 21(2):. PubMed ID: 31947693 [TBL] [Abstract][Full Text] [Related]
11. Sorafenib ameliorates bleomycin-induced pulmonary fibrosis: potential roles in the inhibition of epithelial-mesenchymal transition and fibroblast activation. Chen YL; Zhang X; Bai J; Gai L; Ye XL; Zhang L; Xu Q; Zhang YX; Xu L; Li HP; Ding X Cell Death Dis; 2013 Jun; 4(6):e665. PubMed ID: 23764846 [TBL] [Abstract][Full Text] [Related]
12. Inflammation and immunity in IPF pathogenesis and treatment. Heukels P; Moor CC; von der Thüsen JH; Wijsenbeek MS; Kool M Respir Med; 2019 Feb; 147():79-91. PubMed ID: 30704705 [TBL] [Abstract][Full Text] [Related]
13. New therapeutics based on emerging concepts in pulmonary fibrosis. Sontake V; Gajjala PR; Kasam RK; Madala SK Expert Opin Ther Targets; 2019 Jan; 23(1):69-81. PubMed ID: 30468628 [TBL] [Abstract][Full Text] [Related]
15. Pathogenesis of idiopathic pulmonary fibrosis. Wolters PJ; Collard HR; Jones KD Annu Rev Pathol; 2014; 9():157-79. PubMed ID: 24050627 [TBL] [Abstract][Full Text] [Related]
16. Treatments in idiopathic pulmonary fibrosis: time for a more targeted approach? Mahendran S; Sethi T QJM; 2012 Oct; 105(10):929-34. PubMed ID: 22647761 [TBL] [Abstract][Full Text] [Related]
18. Osteopontin: an essential regulatory protein in idiopathic pulmonary fibrosis. Zhu X; Ji J; Han X J Mol Histol; 2024 Feb; 55(1):1-13. PubMed ID: 37878112 [TBL] [Abstract][Full Text] [Related]
19. Extracellular matrix remodeling in idiopathic pulmonary fibrosis. It is the 'bed' that counts and not 'the sleepers'. Tomos IP; Tzouvelekis A; Aidinis V; Manali ED; Bouros E; Bouros D; Papiris SA Expert Rev Respir Med; 2017 Apr; 11(4):299-309. PubMed ID: 28274188 [TBL] [Abstract][Full Text] [Related]
20. Role of MicroRNAs in Signaling Pathways Associated with the Pathogenesis of Idiopathic Pulmonary Fibrosis: A Focus on Epithelial-Mesenchymal Transition. Cadena-Suárez AR; Hernández-Hernández HA; Alvarado-Vásquez N; Rangel-Escareño C; Sommer B; Negrete-García MC Int J Mol Sci; 2022 Jun; 23(12):. PubMed ID: 35743055 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]